Integral Diagnostics (IDX.AX) Stock Price
Integral Diagnostics Price
Over the last 14 years Integral Diagnostics grew revenue by 48.9% annually, reaching 788.62 M AUD. Earnings per share have grown at 15.9% per year over the last 13 years. For Integral Diagnostics, the net margin of 2.8% is down versus 4.1% a few years ago. At today's price the dividend yield works out to roughly 3.93%. The payout ratio is around 330% of earnings. The dividend has grown at 5.0% per year over the past 10 years. The consensus 12-month price target for Integral Diagnostics is 3.37 AUD, about 46.7% above where the stock trades today. Of 16 analysts, 14 rate the stock a buy — an overall Buy consensus. The stock trades about 18% above its 52-week low.
Integral Diagnostics stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Integral Diagnostics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Integral Diagnostics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Integral Diagnostics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Integral Diagnostics Price |
|---|---|
| 9/18/2026 | 2.30 AUD |
| 9/17/2026 | 2.35 AUD |
| 9/16/2026 | 2.33 AUD |
| 9/15/2026 | 2.29 AUD |
| 9/14/2026 | 2.26 AUD |
| 9/11/2026 | 2.30 AUD |
| 9/10/2026 | 2.29 AUD |
| 9/9/2026 | 2.31 AUD |
| 9/8/2026 | 2.35 AUD |
| 9/7/2026 | 2.34 AUD |
| 9/4/2026 | 2.30 AUD |
| 9/3/2026 | 2.30 AUD |
| 9/2/2026 | 2.35 AUD |
| 9/1/2026 | 2.32 AUD |
| 8/31/2026 | 2.28 AUD |
| 8/28/2026 | 2.26 AUD |
| 8/27/2026 | 2.31 AUD |
| 8/26/2026 | 2.33 AUD |
| 8/25/2026 | 2.39 AUD |
| 8/24/2026 | 2.26 AUD |
| 8/21/2026 | 2.25 AUD |
| 8/20/2026 | 2.21 AUD |
| 8/19/2026 | 2.24 AUD |
| 8/18/2026 | 2.26 AUD |
| 8/17/2026 | 2.23 AUD |
| 8/14/2026 | 2.24 AUD |
| 8/13/2026 | 2.23 AUD |
| 8/12/2026 | 2.22 AUD |
| 8/11/2026 | 2.22 AUD |
| 8/10/2026 | 2.02 AUD |
Integral Diagnostics Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Integral Diagnostics Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB AUD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM AUD |
| EBITM AUD |
| EBIT MARGIN% |
| NET INCOMEM AUD |
| NET INCOME GROWTH% |
| DIVIDENDDIV.AUD |
| DIVIDEND GROWTHDIV. GROWTH% |
| SHARESM |
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027e | 2028e | 2029e | 2030e | 2031e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.17 | 0.18 | 0.19 | 0.23 | 0.27 | 0.35 | 0.36 | 0.44 | 0.47 | 0.63 | 0.79 | 0.84 | 0.89 | 0.94 | 1.00 | 1.06 |
| 10.60 | 7.19 | 5.59 | 22.75 | 18.10 | 27.01 | 2.87 | 22.91 | 6.59 | 33.69 | 25.68 | 6.22 | 6.09 | 5.29 | 7.27 | 5.18 |
| 37.72 | 36.31 | 37.57 | 38.79 | 26.28 | 26.44 | 23.18 | 22.05 | 95.10 | 95.53 | 21.32 | 21.32 | 21.32 | 21.32 | 21.32 | 21.32 |
| 63.00 | 65.00 | 71.00 | 90.00 | 72.00 | 92.00 | 83.00 | 97.00 | 446.00 | 599.00 | 168.00 | 178.45 | 189.32 | 199.34 | 213.84 | 224.92 |
| 26.00 | 23.00 | 28.00 | 37.00 | 38.00 | 47.00 | 38.00 | 40.00 | 42.00 | 57.00 | 67.00 | 99.00 | 111.00 | 121.00 | 136.00 | – |
| 15.57 | 12.85 | 14.81 | 15.95 | 13.87 | 13.51 | 10.61 | 9.09 | 8.96 | 9.09 | 8.50 | 11.83 | 12.50 | 12.94 | 13.56 | – |
| 11.00 | 15.00 | 15.00 | 20.00 | 23.00 | 31.00 | 14.00 | 25.00 | -60.00 | 4.00 | 21.00 | 41.00 | 49.00 | 54.00 | 63.00 | 80.00 |
| 175.00 | 36.36 | – | 33.33 | 15.00 | 34.78 | -54.84 | 78.57 | -340.00 | -106.67 | 425.00 | 95.24 | 19.51 | 10.20 | 16.67 | 26.98 |
| 0.06 | 0.10 | 0.11 | 0.14 | 0.13 | 0.18 | 0.10 | 0.09 | 0.08 | 0.09 | 0.09 | 0.12 | 0.12 | 0.12 | – | – |
| – | 66.67 | 10.00 | 27.27 | -7.14 | 38.46 | -44.44 | -10.00 | -11.11 | 12.50 | – | 33.33 | – | – | – | – |
| 145.09 | 145.01 | 156.22 | 179.67 | 202.14 | 205.61 | 235.58 | 233.25 | 247.50 | 376.26 | 376.87 | 376.87 | 376.87 | 376.87 | 376.87 | 376.87 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Integral Diagnostics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Integral Diagnostics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Integral Diagnostics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Integral Diagnostics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Integral Diagnostics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Integral Diagnostics stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Integral Diagnostics Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Integral Diagnostics business model & stock analysis
Integral Diagnostics SWOT Analysis
Strengths
Integral Diagnostics Ltd has several notable strengths that contribute to its success in the healthcare industry. Firstly, the company has an extensive network of medical imaging centers, allowing it to reach a wide customer base. This allows for increased market penetration and revenue generation. Additionally, Integral Diagnostics has a strong reputation for providing high-quality diagnostic services, which enhances its competitive advantage. The company also boasts a team of skilled and experienced medical professionals who provide accurate and reliable diagnoses, further solidifying its position in the market.
Despite its strengths, Integral Diagnostics Ltd faces several weaknesses that it needs to address. One weakness is the company's dependency on Medicare reimbursement rates for a significant portion of its revenue. This exposes the business to potential changes in government policies and regulations, which could negatively impact its financial performance. Another weakness is the limited geographical presence of Integral Diagnostics, primarily operating in Australia. This reduces its ability to capitalize on international market opportunities and diversify its revenue streams.
Integral Diagnostics Ltd has identified several opportunities for future growth. With the increasing demand for medical imaging services globally, the company can expand its operations internationally to tap into new markets. By leveraging advancements in technology, such as artificial intelligence and telemedicine, Integral Diagnostics can enhance its service offerings and improve efficiency. Furthermore, partnerships and collaborations with healthcare providers can lead to mutually beneficial arrangements and provide access to a larger patient population.
The healthcare industry poses various threats to Integral Diagnostics Ltd. One major threat is the potential disruption caused by new competitors entering the market with innovative diagnostic technologies or business models. This could challenge the company's market share and competitive position. Additionally, changes in healthcare policies and regulations, both domestically and internationally, could affect reimbursement rates and operational requirements, disrupting Integral Diagnostics' financial performance and operations. Lastly, economic downturns and declines in healthcare spending can impact the overall demand for medical imaging services, creating a threat to the company's revenue generation.
Weaknesses
Despite its strengths, Integral Diagnostics Ltd faces several weaknesses that it needs to address. One weakness is the company's dependency on Medicare reimbursement rates for a significant portion of its revenue. This exposes the business to potential changes in government policies and regulations, which could negatively impact its financial performance. Another weakness is the limited geographical presence of Integral Diagnostics, primarily operating in Australia. This reduces its ability to capitalize on international market opportunities and diversify its revenue streams.
Integral Diagnostics Ltd has identified several opportunities for future growth. With the increasing demand for medical imaging services globally, the company can expand its operations internationally to tap into new markets. By leveraging advancements in technology, such as artificial intelligence and telemedicine, Integral Diagnostics can enhance its service offerings and improve efficiency. Furthermore, partnerships and collaborations with healthcare providers can lead to mutually beneficial arrangements and provide access to a larger patient population.
The healthcare industry poses various threats to Integral Diagnostics Ltd. One major threat is the potential disruption caused by new competitors entering the market with innovative diagnostic technologies or business models. This could challenge the company's market share and competitive position. Additionally, changes in healthcare policies and regulations, both domestically and internationally, could affect reimbursement rates and operational requirements, disrupting Integral Diagnostics' financial performance and operations. Lastly, economic downturns and declines in healthcare spending can impact the overall demand for medical imaging services, creating a threat to the company's revenue generation.
Opportunities
Integral Diagnostics Ltd has identified several opportunities for future growth. With the increasing demand for medical imaging services globally, the company can expand its operations internationally to tap into new markets. By leveraging advancements in technology, such as artificial intelligence and telemedicine, Integral Diagnostics can enhance its service offerings and improve efficiency. Furthermore, partnerships and collaborations with healthcare providers can lead to mutually beneficial arrangements and provide access to a larger patient population.
The healthcare industry poses various threats to Integral Diagnostics Ltd. One major threat is the potential disruption caused by new competitors entering the market with innovative diagnostic technologies or business models. This could challenge the company's market share and competitive position. Additionally, changes in healthcare policies and regulations, both domestically and internationally, could affect reimbursement rates and operational requirements, disrupting Integral Diagnostics' financial performance and operations. Lastly, economic downturns and declines in healthcare spending can impact the overall demand for medical imaging services, creating a threat to the company's revenue generation.
Threats
The healthcare industry poses various threats to Integral Diagnostics Ltd. One major threat is the potential disruption caused by new competitors entering the market with innovative diagnostic technologies or business models. This could challenge the company's market share and competitive position. Additionally, changes in healthcare policies and regulations, both domestically and internationally, could affect reimbursement rates and operational requirements, disrupting Integral Diagnostics' financial performance and operations. Lastly, economic downturns and declines in healthcare spending can impact the overall demand for medical imaging services, creating a threat to the company's revenue generation.
Integral Diagnostics Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Integral Diagnostics historical P/E ratio, EBIT multiple, and P/S ratio
Integral Diagnostics annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Integral Diagnostics's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Integral Diagnostics's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Integral Diagnostics's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Integral Diagnostics shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Integral Diagnostics Dividend History
11 years of dividend payments
Integral Diagnostics dividend history and estimates
Max
Details
Integral Diagnostics dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Integral Diagnostics forecasts and price targets in September 2026
Analyst Price Targets 2026Integral Diagnostics Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 2/16/2027 | 0.06AUD | - | 415.76 MAUD | - | 2026 Q4 |
| 8/24/2026 | 0.06AUD | 0.06AUD | 398.30 MAUD | - | 2026 Q2 |
| 2/24/2026 | 0.06AUD | 0.02AUD | 396.74 MAUD | - | 2025 Q4 |
| 8/25/2025 | 0.06AUD | 0.07AUD | 346.65 MAUD | - | 2025 Q2 |
| 2/25/2025 | 0.04AUD | 0.04AUD | 253.24 MAUD | - | 2024 Q4 |
| 8/26/2024 | 0.05AUD | 0.05AUD | 557.81 MAUD | - | 2024 Q2 |
| 2/19/2024 | 0.03AUD | 0.03AUD | 233.43 MAUD | - | 2023 Q4 |
| 2/16/2023 | 0.06AUD | 0.03AUD | 212.45 MAUD | - | 2022 Q4 |
| 7/26/2022 | 0.06AUD | 0.04AUD | 183.49 MAUD | - | 2022 Q2 |
| 1/26/2022 | 0.07AUD | 0.06AUD | 173.77 MAUD | - | 2021 Q4 |
EESG©
Eulerpool ESG Scorecard© for the Integral Diagnostics stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Integral Diagnostics shareholder structure
| % | Name |
|---|---|
5.97360% | |
5.92440% | |
1.95881% | |
1.62578% | |
1.02557% | |
0.70731% |
Integral Diagnostics Beneficial Ownership Filings (SEC 13D/G)
Integral Diagnostics Executives and Management Board
10 members · avg. age 60 · 30 % women
Dr. Ian Kadish
Chief Executive Officer, Managing Director, Executive Director · since 2017
1.25 M AUD
Management
Mr. Craig White
Chief Financial Officer
Mr. John Merity
Company Secretary
Board of Directors
Dr. Manish Mittal
Radiologist Executive Director · since 2025
Mr. Toby Hall
Independent Non-Executive Director and Chair Elect
Ms. Raelene Murphy
Non-Executive Independent Director
Ms. Ingrid Player
Non-Executive Independent Director
Mr. Andrew Fay (60)
Non-Executive Independent Director
Ms. Laura Mcbain
Non-Executive Independent Director
Frequently asked questions about Integral Diagnostics
The business model of Integral Diagnostics Ltd is focused on providing comprehensive diagnostic imaging services to the medical industry. They operate a network of medical imaging clinics across Australia, offering a wide range of imaging services such as MRI, CT, ultrasound, and X-ray scans. Integral Diagnostics aims to deliver high-quality radiology services, ensuring accurate and timely diagnosis for patients. Through their state-of-the-art facilities and experienced medical professionals, they aim to consistently meet the growing demand for advanced imaging services. Integral Diagnostics Ltd aims to enhance patient care and support healthcare providers in delivering effective treatment plans.
Integral Diagnostics Ltd is primarily active in the healthcare industry. With a focus on precision radiology, the company provides a broad range of diagnostic imaging services including X-rays, ultrasounds, CT scans, and more. Integral Diagnostics operates in various sectors within healthcare, including hospitals, medical centers, and specialty clinics. With their high-quality imaging equipment and expert radiologists, Integral Diagnostics plays a crucial role in assisting healthcare professionals in accurate and timely diagnoses. As a leading player in the healthcare industry, Integral Diagnostics Ltd continues to contribute to the advancement of medical imaging and patient care.
The main competitors of Integral Diagnostics Ltd in the market include companies like Sonic Healthcare Ltd, Healius Ltd, and Capitol Health Ltd.
Integral Diagnostics Ltd is a leading medical imaging and radiology service provider in Australia and New Zealand. Established in 2008, the company has quickly grown to become a trusted name in the healthcare industry. With a strong focus on delivering high-quality diagnostic services, Integral Diagnostics utilizes advanced imaging technologies to assist in the accurate detection and diagnosis of various medical conditions. The company prides itself on its team of expert radiologists and state-of-the-art facilities, ensuring patients receive the best possible care. Integral Diagnostics continues to expand its network of clinics, striving to make diagnostic services more accessible to patients across the region.
Integral Diagnostics Ltd has achieved several significant milestones since its establishment. The company has successfully expanded its services and reach, becoming one of the leading providers of radiology and nuclear medicine services in Australia and New Zealand. Integral Diagnostics Ltd has also demonstrated consistent growth and financial success over the years. Additionally, the company has made strategic acquisitions, such as Cape Radiology and Global Diagnostics, further strengthening its position in the market. Integral Diagnostics Ltd continues to invest in advanced technology and quality patient care, striving to deliver exceptional diagnostic imaging services to its customers.
Integral Diagnostics Ltd is primarily present in Australia and New Zealand.
Integral Diagnostics Ltd represents values of excellence, innovation, and integrity. With a strong corporate philosophy emphasizing patient care and diagnostic accuracy, Integral Diagnostics aims to provide the highest quality medical imaging and radiology services. The company's commitment to advanced technology and continuous improvement ensures accurate diagnoses, timely results, and exceptional patient outcomes. By investing in cutting-edge equipment, fostering a collaborative environment, and prioritizing professional development, Integral Diagnostics maintains its status as a trusted provider in the medical imaging field. With a focus on patient-centric care, the company consistently delivers superior diagnostic services, making it a preferred choice for medical professionals and patients alike.
Analysts currently set an average price target of 3.34 AUD for the Integral Diagnostics stock (median: 3.37 AUD), implying +45.4 % versus the latest price. The consensus is based on 16 analyst ratings.
16 analysts currently rate the Integral Diagnostics stock: 14 recommend buying, 1 holding and 1 selling.
Converted at the current exchange rate, the Integral Diagnostics share trades at 1.42 EUR (2.30 AUD).
The Integral Diagnostics share (IDX.AX) is listed on 1 stock exchanges, including: ASX (IDX.AX).
Integral Diagnostics Ltd is a leading Australian diagnostic company that offers medical imaging and pathology services. The company was founded in 1998 and has been listed on the Australian stock exchange since 2015. Integral Diagnostics' business model is based on providing high-quality diagnostic services needed by physicians and other healthcare providers to make accurate diagnoses and ensure the best possible treatment for their patients. Integral Diagnostics operates several business divisions, including radiology services, pathology services, and clinical trials. In the radiology field, the company offers a wide range of diagnostic imaging services, including X-rays, ultrasound, MRI, and CT scans. The company has over 50 radiology practices throughout Australia and a growing presence in New Zealand. The company also offers specialized radiology services such as oncology imaging and intervention, as well as training and workshops for medical staff. Integral Diagnostics also operates a pathology division, which offers a comprehensive range of pathology services including clinical chemistry, hematology, histopathology, and microbiological testing. Integral Diagnostics' pathology services are used for diagnosing diseases and monitoring patients undergoing treatment. In the pathology division, Integral Diagnostics operates 17 laboratories throughout Australia. In addition to radiology and pathology services, Integral Diagnostics also conducts clinical trials. The company provides support to medical researchers in conducting clinical trials and evaluating the effectiveness of new treatment methods. Integral Diagnostics' clinical trials cover a wide range of medical specialties, including oncology, cardiology, and neurology. Integral Diagnostics has a robust IT system that allows for the electronic transmission of patient data and images. The company also operates an online platform through which physicians and medical professionals can access their patient data and images. This facilitates information exchange among doctors and enables quicker diagnosis and treatment of patients. Integral Diagnostics' business model is based on providing high-quality and efficient diagnostic services. The products offered by Integral Diagnostics are essential tools for physicians and medical professionals to make accurate diagnoses and ensure the best possible treatment for patients. When it comes to search engine optimization (SEO), it is important to use relevant keywords that users enter when searching for medical diagnostic services. These may include keywords such as "radiology services," "pathology services," and "clinical trials." The text should also provide the reader with a clear overview of Integral Diagnostics' business model without being too promotional.
The revenue of Integral Diagnostics is 788.62 M AUD. This figure is based on current financial data and reflects the company's business performance.
The profit of Integral Diagnostics is 21.93 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Integral Diagnostics is currently 39.43. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Integral Diagnostics stock.
The price-to-sales ratio (P/S) of Integral Diagnostics is currently 1.10. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Integral Diagnostics stock.
The Eulerpool Quality Score for Integral Diagnostics is 6/10.
The ISIN of Integral Diagnostics is AU000000IDX2. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Integral Diagnostics is IDX.AX. The ticker symbol is used to trade Integral Diagnostics shares on the stock exchange.
Over the past 12 months, Integral Diagnostics paid a dividend of 0.09 AUD . This corresponds to a dividend yield of about 3.93 %. For the coming 12 months, Integral Diagnostics is expected to pay a dividend of 0.12 AUD.
The current dividend yield of Integral Diagnostics is 3.93 %.
Integral Diagnostics pays a dividend, distributed in the months of March, August.
Integral Diagnostics paid dividends every year for the past 10 years.
For the upcoming 12 months, dividends amounting to 0.12 AUD are expected. This corresponds to a dividend yield of 5.23 %.
Integral Diagnostics is assigned to the 'Health' sector.
In the year 2025, Integral Diagnostics distributed 0.09 AUD as dividends.
The dividends of Integral Diagnostics are distributed in AUD.
Integral Diagnostics stock
Integral Diagnostics Peer Group
Integral Diagnostics Ticker
Integral Diagnostics FIGI
All fundamentals and in-depth analysis of Integral Diagnostics
Our stock analysis for Integral Diagnostics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Integral Diagnostics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.